Companies /Healthcare

Abbvie Inc

NYSE: ABBV Drug Manufacturers - General
$256.37
▼ $3.84 (−1.48%) today
Markets closed · 6:36pm ET

Q1 2026 Earnings

Reported Apr 29, 2026, 7:50am ET · SEC source
$2.65
Miss −0.66%
EPS · est. $2.67
$15.0B
Beat +1.93%
Revenue · est. $14.7B
−2.2%
Trailing market
ABBV vs S&P since report
1 quarter
Consecutive EPS beats

Market Reaction

% change · around the report
−4%0+4%Apr 29Apr 30report 7:50am ETearnings+0.7%+4.4%
−4%0+4%Apr 29Apr 30earnings+0.7%+4.4%
ABBV +4.4%S&P 500 +0.7%
−4%0+4%Apr 29Apr 30report 7:50am ETearnings+1.1%+4.4%
−4%0+4%Apr 29Apr 30earnings+1.1%+4.4%
ABBV +4.4%NASDAQ +1.1%
0+3%+6%Apr 28May 7report 7:50am ETearnings+3.2%+1.9%
0+3%+6%Apr 28May 7earnings+3.2%+1.9%
ABBV +1.9%S&P 500 +3.2%
0+3%+6%Apr 28May 7report 7:50am ETearnings+5.5%+1.9%
0+3%+6%Apr 28May 7earnings+5.5%+1.9%
ABBV +1.9%NASDAQ +5.5%
+3.14%
Day of report
+3.64%
Next session
+0.56%
One week
+4.43%
30 days

S&P 500 over the same 30 days: +6.60%.

Did ABBV Beat Earnings? Q1 2026 Results

AbbVie posted a mixed but broadly constructive first quarter for 2026, delivering revenue of $15.00 billion, up 12.4% year over year and ahead of the $14.72 billion consensus, while adjusted diluted EPS of $2.65 came in just shy of the $2.67 analyst estimate, a miss of 0.66%. The earnings shortfall was largely explained by a $744.00 million pre-tax charge tied to acquired in-process research and development and milestones, which shaved $0.41 per share from adjusted results. The immunology franchise carried the quarter, generating $7.29 billion in segment revenue, with Skyrizi climbing 30.9% to $4.48 billion and Rinvoq rising 23.3% to $2.12 billion, more than compensating for Humira's continued erosion to $688.00 million. Neuroscience added further momentum, growing 26.0% to $2.88 billion. Encouraged by the quarter's performance, AbbVie raised its full-year 2026 adjusted EPS guidance to $14.08 to $14.28, from the prior range of $13.96 to $14.16, signaling management's confidence that Skyrizi and Rinvoq can sustain the growth trajectory through the rest of the year.

Key Takeaways
  • Skyrizi net revenues grew 30.9% to $4.483 billion, driven by strong U.S. growth of 29.3% and international growth of 39.8%
  • Rinvoq net revenues grew 23.3% to $2.119 billion with broad-based demand
  • Neuroscience portfolio up 26.0% with strong contributions from Botox Therapeutic, Vraylar, and the migraine franchise
  • Botox Cosmetic grew 20.2%, driving aesthetics portfolio improvement
  • Qulipta and Ubrelvy combined grew significantly with 53.6% and 41.4% increases respectively
  • Vyalev reached $201 million in quarterly revenue

“We are off to an excellent start in 2026, with first-quarter results exceeding our expectations. AbbVie's key growth drivers continue to deliver strong performance and support our enhanced full-year outlook.”

AbbVie CEO, on the earnings call

Forward Guidance & Outlook

AbbVie raised its full-year 2026 adjusted diluted EPS guidance to $14.08–$14.28, up from the prior range of $13.96–$14.16. This updated guidance includes an unfavorable impact of $0.41 per share related to acquired IPR&D and milestones expense incurred year-to-date through Q1 2026. The guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond Q1 2026, as both cannot be reliably forecasted.

ABBV YoY Financials

Q1 2026 vs Q1 2025 · SEC filings Q1 2025 Q1 2026
$0$5.0B$10.0B$15.0B$13.3B$15.0BRevenue$9.3B$10.8BGross Profit$3.7B$4.0BOperating Income$1.3B$695.0MNet Income
$0$5.0B$10.0B$15.0BRevenueGross ProfitOperating IncomeNet Income

ABBV Revenue by Segment

Immunology$7.3B+16.4%
Skyrizi$4.5B+30.9%
Neuroscience$2.9B+26.0%
Rinvoq$2.1B+23.3%
Oncology$1.6B−0.2%
Aesthetics$1.2B+7.6%
Humira$688.0M−38.6%
Vraylar$905.0M+18.4%

ABBV Revenue by Geography

United States$11.0B+9.9%
Rest of World$4.0B+19.9%

Figures from SEC filings and company reports. Not investment advice.